Posted by Michael Wonder on 05 Sep 2016
TGA approves new indication for Gazyva
5 September 2016 - The TGA has approved a new use for Roche's CD20 receptor antagonist.
The TGA approved Gazyva on 30 Augusr 2016 for use in combination with bendamustine, following Gazyva maintenance, for use in the treatment of patients with follicular lymphoma who did not respond to, or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
